Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial
(RTTNews) - Alterity Therapeutics (ATHE, ATH.AX) announced that it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA...
Nasdaq News: Markets·18d ago